Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbix Biosystms ( (TSE:MBX) ) has provided an update.
Microbix Biosystems is presenting new results from its novel Quality Assessment Products (QAPs™) platform for Molecular Pathology at the Labquality Days diagnostics conference in Helsinki, showcasing simulated formalin-fixed paraffin-embedded (FFPE) quality control materials designed to standardize and support nucleic-acid testing across laboratories. The data demonstrate that Microbix has created reproducible, homogeneous, and stable FFPE-simulated QC materials suitable for multiple molecular pathology methods and instruments, initially targeting assays for HPV, HSV, and Chlamydia trachomatis; this positions the company to fill a critical quality-control gap for molecular pathology labs, potentially strengthening its role in global diagnostics quality management and inter-laboratory standardization.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems faces significant challenges in financial performance, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, while valuation metrics are unattractive due to a negative P/E ratio. However, the earnings call provides some optimism with operational improvements and a strong financial position, aiming for recovery in fiscal 2026.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a Canadian life sciences company that creates proprietary biological products for human health, including critical ingredients and devices for the global diagnostics industry. Its portfolio spans antigens for immunoassays, laboratory quality assessment products (QAPs™), and QUANTDx™ reference materials used for proficiency testing, assay development, validation, and workflow quality assurance in clinical labs. With over 120 employees and fiscal 2025 revenue of C$18.6 million, Microbix serves diagnostics manufacturers, accreditation bodies, and clinical laboratories in more than 30 countries, and also develops other proprietary products such as the Kinlytic® urokinase thrombolytic drug and DxTM™ sample-collection reagents.
Average Trading Volume: 66,316
Technical Sentiment Signal: Sell
Current Market Cap: C$30.54M
For an in-depth examination of MBX stock, go to TipRanks’ Overview page.